Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
November 18, 2019, Pfizer announced the FDA approval of Abrilada (adalimumab-afzb), a biosimilar to AbbVie’s Humira® (adalimumab).
Download PDF
Return to publications
